Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when
given with isotretinoin in treating patients with recurrent malignant glioma. Erlotinib
hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Isotretinoin may help cells that are involved in the body's immune response to
work better. Giving erlotinib hydrochloride together with isotretinoin may kill more tumor
cells
Phase:
Phase 1
Details
Lead Sponsor:
Comprehensive Cancer Center of Wake Forest University Wake Forest University Health Sciences